- Lobbying
- Lobbying by Brown Rudnick, LLP, on behalf of Lupin Pharmaceuticals, Inc.
Lobbying Relationship
Bills mentioned
H.R.2051: FAST Generics Act of 2017
Sponsor: David McKinley (R-W.Va.)
H.R.2212: CREATES Act of 2017
Sponsor: Tom Marino (R-Pa.)
H.R.749: Lower Drug Costs through Competition Act
Sponsor: Kurt Schrader (D-Ore.)
H.R.2430: FDA Reauthorization Act of 2017
Sponsor: Greg Walden (R-Ore.)
S.974: Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Sponsor: Patrick J. Leahy (D-Vt.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Lisa Layman | SPA, Sen Stabenow (2005-2007); SPA, Sen Graham (2001 - 2004); LA, Sen Bryan (2000); LA, Sen Chafee (1997 - 1999); CBO, PA (1992 - 1996) SPA, Sen. Stabenow; SPA, Sen. Graham, LA, Sen. Bryan, LA, Sen. Chafee; CBO, PA |
Martin Corry | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
U.S. House of Representatives
U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate